A key challenge remains finding a delivery system that enables enough of the mRNA to reach target tissues safely without causing adverse effects. Lipid nanoparticles have been studied since the ...

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential ...

The global lipid nanoparticles market, valued at US$ 820.51 million in 2023, is projected to experience significant growth, with an expected market valuation of US$ 2,387.98 million by 2032. This ...

Oxford Nanoimaging (ONI), a leader in super-resolution microscopy, is revolutionizing lipid nanoparticle (LNP) analysis with ...

The Boston-based company said its gene-editing treatment for people with high cholesterol was well-tolerated with no serious ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.